Research programme: monoclonal antibody anticancer therapeutics - Novelogics Biotechnology

Drug Profile

Research programme: monoclonal antibody anticancer therapeutics - Novelogics Biotechnology

Latest Information Update: 02 Jun 2017

Price : $50

At a glance

  • Originator Novelogics Biotechnology
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 02 Jun 2017 Research programme: monoclonal antibody anticancer therapeutics - Novelogics Biotechnologyies is available for licensing as of 02 Jun 2017. http://novelogics.com/
  • 17 May 2017 Novelogics Biotechnology and The Centre for Drug Research and Development agree to co-develop monoclonal antibody anti-cancer therapeutics for Cancer
  • 17 May 2017 Novelogics Biotechnology plans a phase I trial for Cancer in the first half of 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top